These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1373967)

  • 1. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
    Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
    Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
    Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
    Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
    J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
    Messinger Y; Reaman GH; Ek O; Uckun FM
    Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
    Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
    Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
    Jansen B; Uckun FM; Jaszcz WB; Kersey JH
    Cancer Res; 1992 Jan; 52(2):406-12. PubMed ID: 1370213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.
    Waddick KG; Myers DE; Gunther R; Chelstrom LM; Chandan-Langlie M; Irvin JD; Tumer N; Uckun FM
    Blood; 1995 Dec; 86(11):4228-33. PubMed ID: 7492781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
    Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
    Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.